Published in Blood Weekly, January 26th, 2006
The transaction eliminates approximately $814 thousand in annual dividends and interest and reduces the company's total outstanding common shares from 27,815,419 to 22,955,224.
The company will receive $8 million from the investors for the purchase of zero coupon convertible preferred stock with detachable warrants and will use these proceeds to redeem or buy back the following securities and debt from GMIL: 3,500,000 of series AA preferred stock; 11,186,430 warrants...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.